Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster

Sachi Morita; Noritoshi Kobayashi; Junji Tsurutani; Haruko Daga; Emiko Ohki; Takami Kashiwada; Kentaro Kawakami; Yoshiko Kitagawa; Masaki Maruta; Yasuhiro Fujiwara; Hironobu Minami

Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster

Sachi Morita
, Noritoshi Kobayashi
, Junji Tsurutani
, Haruko Daga
, Emiko Ohki
, Takami Kashiwada
, Kentaro Kawakami
, Yoshiko Kitagawa
, Masaki Maruta
, Yasuhiro Fujiwara
, Hironobu Minami

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

The Japanese Society of Medical Oncology has conducted a questionnaire survey of its members over a 4-year period from 2020 to 2023 as part of the"Survey on the Impact of Anticancer Drug Therapy under the Spread of COVID-19 Infection". By summarizing the results of the questionnaire survey and reviewing the changes in cancer treatment in the aftermath of the COVID-19, focusing on the results of the 2023 survey which was conducted after the disease became category V infectious disease. It became clear that the COVID-19 not only had an impact on medical professionals and treatment choices but also had a significant impact on end-of-life care. This work was supported by MHLW Special Research Program (Grant Number JPMH20CA2046) and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization(Program Grant Number JPMH21HA2011, JPMH23HA2011 and JPMH24HA2015).

本文言語	英語
ページ（範囲）	573-576
ページ数	4
ジャーナル	Gan to kagaku ryoho. Cancer & chemotherapy
巻	52
号	8
出版ステータス	出版済み - 01-08-2025
外部発表	はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

腫瘍学
癌研究

他のファイルとリンク

引用スタイル

@article{e19f6c51c1154cbab9f89a309c2ac980,

title = "Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster",

abstract = "The Japanese Society of Medical Oncology has conducted a questionnaire survey of its members over a 4-year period from 2020 to 2023 as part of the{"}Survey on the Impact of Anticancer Drug Therapy under the Spread of COVID-19 Infection{"}. By summarizing the results of the questionnaire survey and reviewing the changes in cancer treatment in the aftermath of the COVID-19, focusing on the results of the 2023 survey which was conducted after the disease became category V infectious disease. It became clear that the COVID-19 not only had an impact on medical professionals and treatment choices but also had a significant impact on end-of-life care. This work was supported by MHLW Special Research Program (Grant Number JPMH20CA2046) and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization(Program Grant Number JPMH21HA2011, JPMH23HA2011 and JPMH24HA2015).",

author = "Sachi Morita and Noritoshi Kobayashi and Junji Tsurutani and Haruko Daga and Emiko Ohki and Takami Kashiwada and Kentaro Kawakami and Yoshiko Kitagawa and Masaki Maruta and Yasuhiro Fujiwara and Hironobu Minami",

year = "2025",

month = aug,

day = "1",

language = "English",

volume = "52",

pages = "573--576",

journal = "Gan to kagaku ryoho. Cancer \& chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "8",

}

TY - JOUR

T1 - Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster

AU - Morita, Sachi

AU - Kobayashi, Noritoshi

AU - Tsurutani, Junji

AU - Daga, Haruko

AU - Ohki, Emiko

AU - Kashiwada, Takami

AU - Kawakami, Kentaro

AU - Kitagawa, Yoshiko

AU - Maruta, Masaki

AU - Fujiwara, Yasuhiro

AU - Minami, Hironobu

PY - 2025/8/1

Y1 - 2025/8/1

N2 - The Japanese Society of Medical Oncology has conducted a questionnaire survey of its members over a 4-year period from 2020 to 2023 as part of the"Survey on the Impact of Anticancer Drug Therapy under the Spread of COVID-19 Infection". By summarizing the results of the questionnaire survey and reviewing the changes in cancer treatment in the aftermath of the COVID-19, focusing on the results of the 2023 survey which was conducted after the disease became category V infectious disease. It became clear that the COVID-19 not only had an impact on medical professionals and treatment choices but also had a significant impact on end-of-life care. This work was supported by MHLW Special Research Program (Grant Number JPMH20CA2046) and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization(Program Grant Number JPMH21HA2011, JPMH23HA2011 and JPMH24HA2015).

AB - The Japanese Society of Medical Oncology has conducted a questionnaire survey of its members over a 4-year period from 2020 to 2023 as part of the"Survey on the Impact of Anticancer Drug Therapy under the Spread of COVID-19 Infection". By summarizing the results of the questionnaire survey and reviewing the changes in cancer treatment in the aftermath of the COVID-19, focusing on the results of the 2023 survey which was conducted after the disease became category V infectious disease. It became clear that the COVID-19 not only had an impact on medical professionals and treatment choices but also had a significant impact on end-of-life care. This work was supported by MHLW Special Research Program (Grant Number JPMH20CA2046) and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization(Program Grant Number JPMH21HA2011, JPMH23HA2011 and JPMH24HA2015).

UR - https://www.scopus.com/pages/publications/105015230181

UR - https://www.scopus.com/pages/publications/105015230181#tab=citedBy

M3 - Article

C2 - 40840906

AN - SCOPUS:105015230181

SN - 0385-0684

VL - 52

SP - 573

EP - 576

JO - Gan to kagaku ryoho. Cancer & chemotherapy

JF - Gan to kagaku ryoho. Cancer & chemotherapy

IS - 8

ER -

Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster

抄録

UN SDG

All Science Journal Classification (ASJC) codes

他のファイルとリンク

フィンガープリント

引用スタイル